Medline Industries

Medline Industries

James Mills founded Medline in 1966 after pivoting from a hospital-garment manufacturing business into a full-spectrum medical-supply operation. His sons, Charlie and Andy Mills, later took the reins and built the firm into an industrial-scale distribution platform that competes directly with publicly traded giants like Owens & Minor and Cardinal Health. The wealth origin is straightforward: multidecade compounding of a family-owned manufacturing and logistics business that became essential to US healthcare infrastructure. Medline operates across the acute-care, post-acute, and consumer-health markets, distributing over 300,000 products including surgical drapes, exam gloves, durable medical equipment, and proprietary-branded skin-care and infection-prevention lines. The firm runs a direct-distribution model through a network of more than 50 distribution centers, serving hospitals, nursing homes, surgery centers, and home-health agencies nationwide. A landmark transaction came in June 2021 when Blackstone, Carlyle, and Hellman & Friedman acquired a majority equity stake, retaining the Mills family as significant ongoing shareholders. The consortium raised nearly $20 billion in debt financing for the deal, making it one of the largest private-equity healthcare buyouts on record. The 2021 buyout layered institutional governance onto a family-run enterprise that had long operated with limited external disclosure. Medline employs roughly 35,000 people globally and reports annual revenue exceeding $20 billion. In September 2023, the company appointed Jim Boyle — a seasoned healthcare operating executive — as President and COO, signaling a continued professionalization push under private-equity stewardship. The Mills family maintains governance influence through continued board representation and retained equity, while the PE sponsors drive efficiency and debt-servicing discipline across the distribution network. Medline's structural differentiator is its dual identity: a family-founded operating company that now functions as a consortium-backed, scaled distribution platform with no direct public-market equivalent. Unlike pure-play distributors, Medline manufactures a significant portion of its own product lines, capturing margin across the value chain. The 2021 recapitalization allowed the Mills family to extract significant liquidity while keeping the operating entity private, insulating strategic decisions from quarterly earnings pressure while the new sponsors pursue operational improvements.